Mirabegron Formulation

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses a novel pharmaceutical composition for the topical or transdermal administration of mirabegron, a beta-3 adrenergic receptor agonist used in overactive bladder treatment. By combining mirabegron with high concentrations of dimethyl sulfoxide (DMSO), sometimes mixed with monoalcohols, glycols, or other excipients, the invention allows for effective penetration of mirabegron through the skin to target subcutaneous fat tissue. This enables localized reduction in fat (lipolysis), with less risk of systemic side effects compared to oral or injectable formulations. The invention is particularly useful for treating obesity, lipedema, or cosmetic reduction of local fat.

Use CasesContent extracted from patent full text and abstract with AI.

• Medical treatment of obesity through localized reduction of subcutaneous adipose tissue via topical or transdermal application of mirabegron.
• Therapeutic management of lipedema by reducing fat deposits in affected extremities.
• Cosmetic applications for non-invasive, localized body contouring and fat reduction.
• Potential management of metabolic complications associated with obesity through local fat reduction.
• Delivery of beta-3 adrenergic agonists to subcutaneous tissues for research or medical therapies requiring direct adipose action.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables effective transdermal delivery of mirabegron, overcoming its poor solubility and skin permeability in previous formulations.
• Reduces systemic side effects by localizing drug action to subcutaneous fat tissue.
• Non-invasive and patient-friendly compared to injections or oral medications.
• Supports both therapeutic (obesity and lipedema) and cosmetic applications (local fat reduction).
• Flexible formulation as gel, spray, cream, etc., enhancing versatility and patient adherence.
• Potentially increases efficacy through sustained and controlled delivery at target site.
• Improved patient compliance by avoiding gastrointestinal or neurological side effects associated with systemic doses.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a composition for topical and/or transdermal administration comprising mirabegron or a salt thereof, wherein the composition comprises: a) mirabegron or a salt thereof in a range from ≥ 0.01 wt.-% to ≤ 25 wt.-%; and b) a solvent selected from: - dimethyl sulfoxide (DMSO) in a range from ≥ 5 wt.-% to ≤ 99.99 wt.-%; or - a mixture of dimethyl sulfoxide in a range from ≥ 5 wt.-% to ≤ 97.99 wt.-%, and a further solvent selected from i) a monoalcohol in a range from ≥ 5 wt.-% to ≤ 94.99 wt.-%, or ii) glycerol, a glycol, a polyethylene glycol, a glycol ether, mixtures thereof, or mixtures with a monoalcohol in a range from ≥ 5 wt.-% to ≤ 60 wt.-%, or iii) water in a range from ≥ 2 wt.-% to ≤ 10 wt.-%; wherein the wt.-% are based on a total weight of the composition of 100 wt.-%.